New Jersey Technology Council Names Dendrite's Garry Johnson `CIO of

New Jersey Technology Council Names Dendrite's Garry Johnson `CIO of the Year'; Johnson Recognized for Innovative Leadership and Applicable Understanding of Industry Dynamics

To download high-resolution, print-ready JPEG images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption

To download high-resolution, print-ready JPEG images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption

To download high-resolution, print-ready JPEG images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption

To download high-resolution, print-ready JPEG images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption

To download high-resolution, print-ready JPEG images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption

    Pharmaceutical Writers/Business Editors
    MULTIMEDIA AVAILABLE:
    http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4888725

    BEDMINSTER, N.J.--(BUSINESS WIRE)--May 16, 2005--Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of sales, marketing, clinical and compliance solutions for the life sciences industry, today announced that Garry D. Johnson, its senior vice president and Chief Technology Officer (CTO) was named 2005 "CIO of the Year" by the New Jersey Technology Council (NJTC) at its first annual CIO Award program.
    The award honored Johnson for continued excellence and model leadership in his position. Johnson was selected among an outstanding group of executives based on his ability to create and execute innovative strategies that produced measurable financial benefits for Dendrite. Judges recognized Johnson's ability to translate his deep understanding of market and workforce dynamics into executable strategies, including the creation of an offshore development center in India leading to considerable annual savings for the company.
    As the leader of Dendrite's information technology (IT) group, Johnson leads a team of more than 900 employees located on three continents. He is responsible for creating and directing Dendrite's Technical Center of Excellence, which consists of 350 technology professionals in multiple U.S. locations and is critical to providing a broad range of hardware and software support.
    Additionally, Johnson is responsible for Dendrite's global product development, program management, client implementations and ongoing service delivery including managed hosting services, help desk, training and hardware services.
    "Garry's commitment, dedication and steadfast vision for excellence have greatly helped Dendrite expand global operations while maintaining the highest level of quality products and services," said Paul Zaffaroni, President and Chief Operating Officer (COO), Dendrite International. "His foresight, leadership and unwavering focus on customer needs, makes him a critical member of our leadership team."

    ABOUT DENDRITE

    Founded in 1986, Dendrite International (NASDAQ: DRTE) provides award-winning sales, marketing, clinical and compliance solutions and services to global pharmaceutical and other life sciences companies. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

    Note: Dendrite is a registered trademark of Dendrite International, Inc.

    This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4888725

--30--BS/ny*

CONTACT: Racepoint Group, Inc. Palmer Reuther, 781-487-4606 preuther@racepointgroup.com

KEYWORD: NEW JERSEY INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY MANAGEMENT CHANGES PHOTO PHOTOWIRE SOURCE: Dendrite International, Inc. PHOTO: 45330

Copyright Business Wire 2005